ApoB, the blood value that shows what LDL cholesterol alone does not

What is ApoB, and what does this value count?

Apolipoprotein B is a protein on the shell of those fat particles that can damage your arteries. Exactly one molecule of it sits on each of these particles. When you have ApoB measured, you therefore get an estimate of how many such particles are travelling in your blood. LDL cholesterol measures how much cargo is in transit; ApoB counts how many carriers are on the road.

The European guideline on the management of dyslipidaemias puts it the same way. All ApoB-carrying particles, meaning VLDL, the remnants of triglyceride-rich particles and LDL, each contain a single ApoB molecule.

There are two variants. ApoB-48 is formed in the intestine, ApoB-100 only in the liver. ApoB-100 sits on the particles that are relevant for your arteries, and lipoprotein(a) carries it as well.

Why is my LDL cholesterol not always enough?

Because an amount of cargo says nothing about how many carriers it is spread across. Most of the time both numbers run in parallel. In about 20 percent of patients they diverge, according to the European guideline, particularly in diabetes, high triglycerides, obesity, metabolic syndrome, or a very low LDL on ongoing therapy.

The German Cardiac Society (DGK) is more explicit at this point. In exactly these situations ApoB is proportionally more raised than LDL cholesterol and is the better measure there for assessing your risk. The divergence runs in both directions: ApoB can also place your risk lower than LDL cholesterol suggests.

How far apart can the two values be?

Further than most people expect. An analysis of 12,688 adults from a US health survey shows that at an LDL cholesterol of 100 mg/dl, 95 percent of participants had an ApoB between 66 and 99 mg/dl. At higher LDL this range grew wider. The analysis covered people not taking statins and without markedly raised triglycerides.

Two details from it are often misrepresented online. First, the mean ApoB value lies below the LDL value. LDL values of 55, 70, 100 and 190 mg/dl correspond to mean ApoB values of 49, 60, 80 and 140 mg/dl. So anyone claiming that ApoB must lie above LDL is wrong.

Second, even metabolically healthy people sometimes diverged considerably. A European analysis of 293,876 adults from the UK Biobank arrives at the same picture. At an LDL cholesterol of 130 mg/dl, ApoB there ranged from 85.8 to 108.8 mg/dl; at triglycerides of 115 mg/dl it ranged from 67.8 to 147.4 mg/dl. Neither of these analyses provides a threshold above which a divergence counts as meaningful.

My laboratory says normal, so is my ApoB good?

Not necessarily. Your laboratory report shows you a reference range, meaning the spread in a comparison population. A guideline, by contrast, states target values, meaning treatment goals for a particular risk category. These are two different things, and confusing them is the most common mistake with this value.

The professional societies see the problem themselves. A joint paper from the European Atherosclerosis Society and European laboratory medicine explicitly calls for laboratories to flag abnormal lipid values against therapeutic decision thresholds rather than against the reference range.

An ApoB of 130 mg/dl is marked as normal by many laboratories. Yet it lies above every target value in the European guideline, and according to the assessment of the US lipid society only about one untreated adult in ten is higher.

Check the unit as well. German laboratories often report ApoB in g/l, where 1 g/l corresponds exactly to 100 mg/dl. In women the upper limit of the reference range is typically lower than in men.

What do the guidelines actually say about ApoB?

They distinguish two things that often get mixed up. As a treatment target, LDL cholesterol remains first in line in Europe, with ApoB behind it. As a measurement, the same guideline explicitly also permits ApoB in place of LDL cholesterol, for screening, diagnosis and treatment. Both hold at the same time.

The reticence about the treatment target has an understandable reason. The ApoB target values are derived from the LDL targets and have not been comprehensively examined in large treatment trials. The DGK takes the same view.

For risk assessment, by contrast, measuring ApoB sits at the same level as LDL cholesterol and non-HDL cholesterol. Anyone writing that ApoB has replaced LDL cholesterol as the primary treatment target is misrepresenting the European guideline.

Internationally the picture is not uniform, and that belongs to an honest account. Since 2021 the Canadian society has explicitly permitted using ApoB in place of LDL cholesterol for screening and treatment targets. The new US guideline of 2026 also upgrades ApoB, for instance when the LDL targets have been reached and triglycerides remain high. It too does not make ApoB the general primary target.

The European update of 2025 did not revise ApoB; there are no new target values there. The guideline of 2019 remains authoritative.

Who benefits most from the measurement?

Precisely when LDL cholesterol becomes unreliable. The European guideline and the DGK name a short list for this.

• diabetes mellitus
• raised triglycerides
• obesity or metabolic syndrome
• a very low LDL cholesterol on ongoing lipid-lowering therapy
• suspected familial dyslipidaemia
• a persisting risk even though the LDL targets have been reached

If none of these features applies and your lipid profile is unremarkable, the additional information gained is limited. NOA Health offers the measurement described here itself, and that is precisely why we say it plainly. Not everyone needs it.

Do I have to be fasting, and what matters about the laboratory?

You do not have to be fasting for ApoB. The European guideline justifies this on the grounds that the particles from your last meal typically account for less than one percent of total ApoB. It also considers the measurement quality of ApoB better than measuring or calculating LDL cholesterol and non-HDL cholesterol.

The US lipid society names one exception. Where triglycerides are markedly raised, this one-percent assumption does not hold. In practice blood is nevertheless often drawn fasting, but because of the accompanying values such as triglycerides, not because of ApoB.

For follow-up measurements one point matters. The good measurement quality holds within one method. Between different laboratories and methods, ApoB values are not readily comparable, because a comparison study across ten laboratories and five methods found a spread of around 14 percent. If you want to see the trend, measure at the same laboratory.

According to the US lipid society, the value can be temporarily altered by a marked change in weight, a new disease of the kidney, liver or thyroid, a new or worsened blood sugar situation, an inflammatory condition, and newly started medicines that affect lipid metabolism. If you were acutely ill shortly beforehand, it is better to wait.

What does measuring ApoB cost?

ApoB is not part of the statutory check-up. Four lipid values are provided for there, namely total cholesterol, LDL, HDL and triglycerides. Between the ages of 18 and 35, even this blood panel is only provided for where there is a corresponding risk profile, for instance a family history, obesity or high blood pressure. Only from 35 does it belong to it unconditionally.

There is a statutory item nonetheless. It is valued at €8.83, as of 2026, after the laboratory reform of 1 January 2025 reduced the technical laboratory services. Where a medical indication exists, the test is covered by statutory health insurance. Your doctor decides on that.

That people nevertheless often pay themselves in practice has two factual reasons. The value belongs to the special laboratory, whose billing requires authorisation of the performing laboratory. And practices receive a bonus for ordering laboratory services economically.

This bonus tapers off when the laboratory costs ordered rise above the quarterly average across all treatment cases. In general medicine the tapering begins at €1.42 and ends at €3.37. It is therefore not your single measurement that is the problem, but the sum across many patients. The laboratory service itself is remunerated to the laboratory in every case.

As a self-payer, the laboratory costs alone lie between €11.66 and €15.15 under the official German medical fee schedule, with €13.41 being usual for laboratory services. Blood collection and the doctor's fee are added to that.

Is there a target value for me at 30?

No, and that should be said openly. The ApoB target values hang on a risk category, and that is determined with calculators intended for people aged 40 and over. A 30-year-old without pre-existing disease formally lands at low risk, and for this category the European guideline states no ApoB target value at all. Anyone who reads a concrete number online for healthy 30-year-olds is reading an invention.

A different picture, one the German Cardiac Society uses itself, is more useful. What matters is not only how high your value is, but how long it stays high. The society speaks of cholesterol-years, similar to pack-years in smoking. The European update of 2025 puts it in terms of a higher LDL burden in younger years being associated with a higher later risk.

For you at 30 this means that a single number today says less than its trend across decades. Placing it in context belongs in a medical assessment that considers ApoB together with your lipid profile, your family history, your blood pressure and your circumstances. How blood values can be read together is covered under understanding blood values and biomarkers.